ÂÜÀòÂÒÂ×

Sacha Dopheide, PhD has more than 15 years of experience in the in vitro diagnostic device industry, ranging from point-of-care devices to laboratory analyzers. She currently serves as the company’s Chief Technology Officer and has held an executive leadership role within Lumos Diagnostics since its acquisition of Kestrel Bioscience in 2017. Dr. Dopheide has experience managing the full range of product development for both immunoassays and their accompanying electronic readers from proof of concept through development, verification and external validation trials. Dr. Dopheide has taken a leading role in identification and due diligence of M&A targets and integration activities. She also leads the Lumos Diagnostic service business unit’s business development activities, including directly conducting global market research, establishing partnerships and generating strategic product roadmaps for new tests.